Breast-cancer cell proliferation
Potential benefit studied: Reduction in Ki-67, a marker of tumour-cell multiplication
Supporting researchThis is cancer research, not a product treatment claim. These studies do not establish that Longevity or Mobility prevents, treats or cures cancer.
A human presurgery study found that boswellia produced a favourable change in Ki-67, a marker of tumour-cell multiplication.
Twenty-two patients enrolled; 20 received 2,400mg/day of Boswellia serrata for a median of 11 days, and 18 had evaluable tissue. Their biopsy-to-surgery marker changes were compared with tissue from 18 untreated patients.
This short oncology study used a specific extract and dose, not Mobility or its finished blend. It does not show that a retail supplement treats breast cancer. Supplement use around surgery requires the treating team's guidance.
The doses above describe research, not personal dosing instructions. Ingredient studies do not diagnose symptoms or establish medical suitability. Discuss medicines, existing conditions and treatment decisions with an appropriate healthcare professional.